Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 23, 2025

Astragaloside IV (C 41 H 68 O 14 , AS-IV) is a naturally occurring saponin isolated from the root of Astragalus membranaceus widely used traditional Chinese botanical drug in medicine. In recent years, AS-IV has attracted considerable attention for its hepatoprotective properties, which are attributed to low toxicity as well anti-inflammatory, antioxidant and antitumour effects. Numerous preclinical studies have demonstrated potential prevention treatment various liver diseases, including multifactorial injury, metabolic-associated fatty disease, fibrosis cancer. Given promising growing interest research, this review provides comprehensive summary current state research on effects AS-IV, based literature available databases such CNKI, PubMed, ScienceDirect, Google Scholar Web Science. The mechanisms multifaceted, encompassing inhibition inflammatory responses, reduction oxidative stress, improvement insulin leptin resistance, modulation gut microbiota, suppression hepatocellular carcinoma cell proliferation induction tumour apoptosis. Notably, key molecular pathways involved these include Nrf2/HO-1, NF-κB, NLRP3/Caspase-1, JNK/c-Jun/AP-1, PPARα/FSP1 Akt/GSK-3β/β-catenin. Toxicity indicate that high level safety. addition, discusses sources, physicochemical challenges development clinical application providing valuable insights into agent pharmaceutical nutraceutical industries.

Язык: Английский

---

Molecular Mechanisms of Pyroptosis in Non-alcoholic Steatohepatitis and Feasible Diagnosis and Treatment Strategies

Pharmacological Research, Год журнала: 2025, Номер unknown, С. 107754 - 107754

Опубликована: Апрель 1, 2025

Pyroptosis is a distinct form of cell death that plays critical role in intensifying inflammatory responses. It primarily occurs via the classical pathway, non-classical caspase-3/6/7/8/9-mediated pathways, and granzyme-mediated pathways. Key effector proteins involved pyroptosis process include gasdermin family pannexin-1 protein. intricately linked to onset progression non-alcoholic steatohepatitis (NASH). During development NASH, factors such as pyroptosis, innate immunity, lipotoxicity, endoplasmic reticulum stress, gut microbiota imbalance interact interweave, collectively driving disease progression. This review analyzes molecular mechanisms its pathogenesis NASH. Furthermore, it explores potential diagnostic therapeutic strategies targeting offering new avenues for improving diagnosis treatment

Язык: Английский

---

Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification

ACS Omega, Год журнала: 2025, Номер unknown

Опубликована: Апрель 29, 2025

Язык: Английский

---

Decreasing interleukin-6 levels after TIPS predict outcomes in decompensated cirrhosis

JHEP Reports, Год журнала: 2024, Номер 7(4), С. 101308 - 101308

Опубликована: Дек. 18, 2024

Transjugular intrahepatic portosystemic shunt (TIPS) effectively treats complications of cirrhosis. Systemic inflammation (SI) is linked to acute-on-chronic liver failure (ACLF) and liver-related death. We aimed assess the trajectory clinical impact SI parameters after TIPS implantation. Consecutive patients undergoing elective implantation covered for recurrent/refractory ascites or portal-hypertensive bleeding at Medical University Vienna (NCT03409263; n = 58) Hannover School (NCT04801290, 51) were included. IL-6 was assessed baseline (BL), 3 months (M3) up 6 (M6; cohort) 9 (M9; follow-up; C-reactive protein (CRP) lipopolysaccharide-binding (LBP) in cohort only. In 109 (66.1% male, median age 57 years) receiving mainly (72.4%) by indication BL levels 10.5 pg/ml; 41.3% (n 45/109) exhibiting ≥14 pg/ml. From M3, decreased 63.8% 37/58; 68.6% 35/51; patients, respectively. Similar rates decreases observed also CRP (in 62.1%) LBP 77.4%). A considerable reduction (≥50% baseline) noted 41 (37.6%) during follow-up. Competing risk regression combined adjusted age, albumin, model end-stage disease revealed that decrease M3 an independently protective factor development ACLF (adjusted subdistribution hazard ratio [asHR]: 0.26; 95% CI: 0.09-0.77; p 0.016) death (asHR: 0.07-0.95; 0.042). leads a sustained bacterial translocation with decompensated Decreasing three indicate lower major driver progression advanced chronic (dACLD). This study demonstrates systemic (i.e. interleukin-6 [IL-6]) sustainedly transjugular Thus, our results suggest reduces clinically meaningful way.

Язык: Английский

---

Pyroptosis in Liver Failure: A Twisted Firestarter

Journal of Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Авг. 1, 2024

Язык: Английский

---